Inventor · disambiguated record
Don J. Diamond
Also filed as: DIAMOND DON · DIAMOND DON J · DIAMOND DON JEFFREY
45 granted patents·21 pending applications·583 citations·filing 1998–2025
98Inventor score
Top patents by PatentIndex Score
66 records- 0194US11690908B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2021·Granted Jul 4, 2023·3 cites·10 claims
- 0294US11116834B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2017·Granted Sep 14, 2021·10 cites·11 claims
- 0394US10961538B2Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapyHOPE CITY·Filed 2019·Granted Mar 30, 2021·7 cites·15 claims
- 0494US8580276B2Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereofDIAMOND DON·Filed 2010·Granted Nov 12, 2013·29 cites·10 claims
- 0594US6251399B1Immuno-reactive peptide CTL epitopes of human cytomegalovirusHOPE CITY·Filed 2000·Granted Jun 26, 2001·71 cites·9 claims
- 0693US9453227B2Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapyHOPE CITY·Filed 2013·Granted Sep 27, 2016·68 cites·9 claims
- 0792US12161714B2Use of endogenous viral vaccine in chimeric antigen receptor T cell therapyHOPE CITY·Filed 2023·Granted Dec 10, 2024·1 cites·6 claims
- 0892US11141492B2Anticancer combinationsHOPE CITY·Filed 2015·Granted Oct 12, 2021·7 cites·14 claims
- 0992US10100314B2Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapyHOPE CITY·Filed 2016·Granted Oct 16, 2018·13 cites·19 claims
- 1092US9675689B2Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereofHOPE CITY·Filed 2013·Granted Jun 13, 2017·6 cites·23 claims
- 1192US6843992B2Immuno-reactive peptide CTL epitopes of human cytomegalovirusHOPE CITY·Filed 2003·Granted Jan 18, 2005·32 cites·6 claims
- 1291US10584339B2Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapyHOPE CITY·Filed 2018·Granted Mar 10, 2020·9 cites·15 claims
- 1390US6770749B2P53-specific T cell receptor for adoptive immunotherapyHOPE CITY·Filed 2001·Granted Aug 3, 2004·46 cites·8 claims
- 1489US10603375B2Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereofHOPE CITY·Filed 2017·Granted Mar 31, 2020·2 cites·13 claims
- 1589US9974854B2Synthetic conjugate of CpG DNA and T-help/CTL peptideHOPE CITY·Filed 2015·Granted May 22, 2018·3 cites·10 claims
- 1688US9931395B2MVA vaccine for delivery of a UL128 complex and preventing CMV infectionHOPE CITY·Filed 2015·Granted Apr 3, 2018·6 cites·20 claims
- 1788US7256037B2Modified vaccinia Ankara expressing p53 in cancer immunotherapyHOPE CITY·Filed 2003·Granted Aug 14, 2007·23 cites·5 claims
- 1888US7163685B2Human cytomegalovirus antigens expressed in MVA and methods of useHOPE CITY·Filed 2004·Granted Jan 16, 2007·23 cites·7 claims
- 1988US6733973B2Diagnostic reagents for human cytomegalovirus and methods of useHOPE CITY·Filed 2001·Granted May 11, 2004·20 cites·2 claims
- 2088US6726910B2Immuno-reactive peptide CTL epitopes of human cytomegalovirusHOPE CITY·Filed 2003·Granted Apr 27, 2004·19 cites·11 claims
- 2187US6074645AImmuno-reactive peptide CTL epitopes of human cytomegalovirusHOPE CITY·Filed 1998·Granted Jun 13, 2000·62 cites·4 claims
- 2286US12478672B2Use of triplex CMV vaccine in CAR T cell therapyHOPE CITY·Filed 2023·Granted Nov 25, 2025·0 cites·10 claims
- 2386US12150987B2MVA vaccine for delivery of a UL128 complex and preventing CMV infectionHOPE CITY·Filed 2023·Granted Nov 26, 2024·0 cites·26 claims
- 2486US6632435B1CTL epitope analogsHOPE CITY·Filed 2000·Granted Oct 14, 2003·18 cites·5 claims
- 2586US6562345B1Immuno-reactive peptide CTL epitopes of human cytomegalovirusHOPE CITY·Filed 2000·Granted May 13, 2003·15 cites·1 claims
- 2685US12337032B2Genetically stable recombinant modified vaccinia Ankara (RMVA) vaccines and methods of preparation thereofHOPE CITY·Filed 2022·Granted Jun 24, 2025·0 cites·16 claims
- 2785US6727093B2HCMV-reactive T cells and uses thereforHOPE CITY·Filed 2002·Granted Apr 27, 2004·13 cites·6 claims
- 2884US10376575B2MVA vaccine for delivery of a UL128 complex and preventing CMV infectionHOPE CITY·Filed 2018·Granted Aug 13, 2019·3 cites·20 claims
- 2983US10596254B2Synthetic conjugate of CpG DNA and T-help/CTL peptideHOPE CITY·Filed 2018·Granted Mar 24, 2020·1 cites·8 claims
- 3082US6544521B2Immunoreactive peptide CTL epitopes of human cytomegalovirus pp150HOPE CITY·Filed 2001·Granted Apr 8, 2003·16 cites·16 claims
- 3181US2024156928A1Bi-specific targeted chimeric antigen receptor t cellsHOPE CITY·Filed 2024·Application pending·0 cites
- 3279US6951651B2CTL epitope analogsHOPE CITY·Filed 2003·Granted Oct 4, 2005·7 cites·8 claims
- 3378US2022378911A1Use of Triplex CMV Vaccine in CAR T Cell TherapyHOPE CITY·Filed 2022·Application pending·0 cites
- 3477US6156317AImmuno-reactive peptide CTL epitopes of human cytomegalovirusHOPE CITY·Filed 1998·Granted Dec 5, 2000·42 cites·12 claims
- 3574US11541114B2Genetically stable recombinant modified vaccinia Ankara (rMVA) vaccines and methods of preparation thereofHOPE CITY·Filed 2020·Granted Jan 3, 2023·0 cites·19 claims
- 3674US10842864B2MVA vaccine for delivery of a UL128 complex and preventing CMV infectionHOPE CITY·Filed 2019·Granted Nov 24, 2020·0 cites·10 claims
- 3774US7160685B2Diagnostic reagents for human cytomegalovirus and methods of useHOPE CITY·Filed 2003·Granted Jan 9, 2007·4 cites·2 claims
- 3873US11717568B2MVA vaccine for delivery of a UL128 complex and preventing CMV infectionHOPE CITY·Filed 2020·Granted Aug 8, 2023·0 cites·13 claims
- 3971US10987420B2Synthetic conjugate of CpG DNA and T-help/CTL peptideHOPE CITY·Filed 2020·Granted Apr 27, 2021·0 cites·8 claims
- 4071US7563448B2Modified vaccinia ankara expressing P53 in cancer immunotherapyHOPE CITY·Filed 2007·Granted Jul 21, 2009·1 cites·6 claims
- 4171US2021113691A1Use of Triplex CMV Vaccine in CAR T Cell TherapyHOPE CITY·Filed 2020·Application pending·0 cites
- 4270US9090673B2Synthetic conjugate of CpG DNA and T-help/CTL peptideDIAMOND DON J·Filed 2004·Granted Jul 28, 2015·3 cites·8 claims
- 4369US11844833B2Expression system for expressing herpesvirus glycoprotein complexesHOPE CITY·Filed 2022·Granted Dec 19, 2023·0 cites·21 claims
- 4469US2021386840A1Bi-specific targeted chimeric antigen receptor t cellsHOPE CITY·Filed 2021·Application pending·0 cites
- 4567US2019247500A1Use of Triplex CMV Vaccine in CAR T Cell TherapyHOPE CITY·Filed 2017·Application pending·0 cites
- 4664US2022241432A1Anticancer combinationsHOPE CITY·Filed 2021·Application pending·0 cites
- 4762US2025215456A1Poxvirus-based vectors produced by natural or synthetic dna and uses thereofHOPE CITY·Filed 2025·Application pending·0 cites
- 4861US11384137B2MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereofHOPE CITY·Filed 2019·Granted Jul 12, 2022·0 cites·4 claims
- 4961US2023097513A1Poxvirus-based vectors produced by natural or synthetic dna and uses thereofHOPE CITY·Filed 2021·Application pending·0 cites
- 5061US2024226283A9Vaccination of hematopoietic stem cell donors with cytomegalovirus triplex compositionHOPE CITY·Filed 2021·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Don J. Diamond files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →